Can neutrophil-to-lymphocyte ratio and proatherogenic risk factors improve the accuracy of pneumonia severity index in the prediction of community acquired pneumonia outcome in healthy individuals?
Department of Pharmacology, Toxicology and Clinical Pharmacology,
School of Medicine, Sarajevo School of Science and Technology
, Sarajevo
, Bosnia and Herzegovina
Aim To investigate influence of neutrophil-to-lymphocyte ratio (NLR) and proatherogenic risk factors to improve the accuracy of pneumonia severity index (PSI) in the prediction of community acquired pneumonia (CAP) outcome in healthy individuals. Methods A retrospective observational cross-sectional study conducted at the Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi”, University Clinical Centre Sarajevo, included 83 patients with the diagnosis of CAP during the period March 2019-March 2021. Once diagnosed with CAP, PSI score was calculated and according to its value the need for hospital treatment was identified. Patients were divided in two groups: low risk of CAP (PSI <90), and high risk of CAP (PSI> 90). Results The overall average hospital stay was 22.76±10.154 days. In the patients diagnosed with CAP, a positive correlation was established between the following parameters PSI score and age (r=0.670; p<0.01), C-reactive protein-CRP (rho=0.287; p<0.01), leukocytes (rho=0.406; p<0.01), NLR (rho=0.313; p<0.01) and platelet to lymphocyte ratio (PLR) (0.296; p<0.05). CRP, leukocytes, NLR and PLR were statistically significantly higher in patients with high risk of CAP compared to patients with low risk of CAP. Diastolic blood pressure, lymphocytes, eosinophils were significantly lower in patients with high risk of CAP (p<0.05;) compared to patients with low risk of CAP (p<0.01). The optimal cut-off value of NLR for CAP patients was 3.089 with an estimated area under curve (AUC) of 0.664. Conclusion Proatherogenic parameters such as age, systolic blood pressure and leukocytes in combination with neutrophil-lymphocyte count ratio could improve accuracy of the pneumonia severity index in community acquired pneumonia outcome.
Hohenthal U, Hurme S, Helenius H, Heiro M, Meurman O, Nikoskelainen J, et al. Utility of Creactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009:1026–32.
2
Kang Y, Fang X, Wang D, Wang X. Factors associated with acute myocardial infarction in older patients after hospitalization with community-acquired pneumonia: a cross-sectional study. BMC Geriatr 2021:113.
3
Mozos I, Malainer C, Horbańczuk J, Gug C, Stoian D, Luca C, et al. Inflammatory markers for arterial stiffness in cardiovascular diseases. Front Immunol 2017:1058.
4
Cortes-Telles C-MJ, A. Neutrophil-tolymphocyte ratio as a serum biomarker associated with community acquired pneumonia. Rev Med Inst Mex Seguro Soc 2018:537–43.
5
Huang Y, Liu A, Liang L, Jiang J, Luo H, Deng W, et al. Diagnostic value of blood parameters for community-acquired pneumonia. Int Immunopharmacol 2018:10–5.
6
Mjid M, Taboubi A, Toujani S, Khaled S, Hedhli S, Cheikhrouhou A, et al. The Neutrophil-lymphocyte ratio in patients with community-acquired pneumonia. European Respiratory Journal 2018:A2620.
7
Spoto S, Lupoi D, Valeriani E, Fogolari M, Locorriere L, Anguissola B, et al. Angeletti S. Diagnostic accuracy and prognostic value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in septic patients outside the intensive care unit. Medicina (Kaunas) n.d.:811.
8
Şahin F, Aslan F, A, Karaçar K, C. Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia? European Respiratory Journal 2019:A4541.
9
Modi A, Kovacs C. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. Cleve Clin J Med 2020:633–9.
10
Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013:974–84.
11
Cavallazzi R, Ramirez J. Community-acquired pneumonia in chronic obstructive pulmonary disease. Curr Opin Infect Dis 2020:173–81.
12
Menéndez R, Méndez R, Aldás I, Reyes S, Gonzalez-Jimenez P, España P, et al. Community-acquired pneumonia patients at risk for early and long-term cardiovascular events are identified by cardiac biomarkers. Chest 2019:1080–91.
13
Ridker P, Hennekens C, Buring J, Rifai N. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000:836–43.
14
Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos M, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008:447–52.
15
Chalmers J, Singanayagam A, Hill A. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008:219–25.
16
Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007:556–73.
17
Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos M, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009:587–91.
18
Feldman C, Anderson R. Platelets and their role in the pathogenesis of cardiovascular events in patients with community-acquired pneumonia. Front Immunol 2020:577303.
19
Singanayagam A, Singanayagam A, Elder D, Chalmers J. Is community-acquired pneumonia an independent risk factor for cardiovascular disease? Eur Respir J 2012:187–96.
20
Ye W, Chen X, Huang Y, Li Y, Xu Y, Liang Z, et al. The association between neutrophilto-lymphocyte count ratio and mortality in septic patients: a retrospective analysis of the MIMIC-III database. J Thorac Dis 2020:1843–55.
21
Henry B, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a metaanalysis. Acta Biomed 2020.
22
Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001:5–14.
23
Karakioulaki M, Stolz D. Biomarkers in pneumoniabeyond procalcitonin. Int J Mol Sci 2019.
24
Kim M, Park J, Lee C, Choi W. Pneumonia severity index in viral community acquired pneumonia in adults. PLoS One 2019:210102.
25
Waterer G. Severity Scores and community-acquired pneumonia. Time to move forward. Am J Respir Crit Care Med 2017:1236–8.
26
Begic E, Obradovic S, Jankovic S, Romanovic R, Djenic N, Dzudovic B, et al. Increased C-reactive protein is associated with major adverse cardiovascular events after STEMI. Erciyes Med J 2020:276–80.
27
Reyes L, Restrepo M, Hinojosa C, Soni N, Anzueto A, Babu B, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med 2017:609–20.
28
Vf C-M, Alvarez K, Weissfeld L, Angus D, Chirinos J, Chang C, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015:264–74.
29
Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, et al. SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis 2017:1486–93.
30
Schuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007:578–85.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
